Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Palonosetron" patented technology

This medication is used to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). It is also used to prevent nausea and vomiting after surgery.

A method for detecting related substances in palonosetron-containing fat emulsion injection

PendingCN122631807AIonic strengthPharmaceutical drug
The application belongs to the technical field of medicine extraction and medicine detection, and discloses a detection method of related substances in palonosetron-containing fat emulsion injection. Methanol is used as a main demulsifier, and a sodium dihydrogen phosphate buffer salt solution with a suitable ionic strength is used for assistance, so that full demulsification is realized under the premise of not introducing a third organic phase; a water bath evaporation and redissolution method is used to enrich target components in the solution after demulsification, so that good chromatographic behavior and complete recovery of the target components are ensured, and the detection sensitivity is effectively improved. The palonosetron and related impurities have good separation degree, the method is simple to operate, accurate to measure, and strong in specificity, and is suitable for the determination of palonosetron related substances in rolapitant palonosetron fat emulsion.
Owner:FBC (SHANGHAI) PHARMACEUTICAL TECHNOLOGY CO LTD

Palonosetron transdermal patch and preparation method thereof

ActiveCN116421581BTransdermal patchAdhesive
The present application belongs to the technical field of medicine, and particularly relates to a palonosetron transdermal patch and a preparation method thereof. The transdermal patch is composed of a backing layer, a drug-loaded pressure-sensitive adhesive layer and an anti-adhesion layer. The drug-loaded pressure-sensitive adhesive layer comprises palonosetron free base, pressure-sensitive adhesive, antioxidant and transdermal absorption promoter. The palonosetron free base accounts for 5% to 20% of the total weight, preferably 5% to 15%; the antioxidant accounts for 0.01% to 0.1% of the total weight; the transdermal absorption promoter accounts for 5% to 10% of the total weight; and the pressure-sensitive adhesive accounts for 74.9% to 89.99%. The palonosetron transdermal patch provided by the present application uses mixed pressure-sensitive adhesive of different groups to improve its adhesion and stability, and can realize slow release of palonosetron free base within 7 days.
Owner:NEW LEADING (CHONGQING) PHARM TECH CO LTD

Precise centrifugal separator for purifying levoparoxol

The precise centrifugal separator comprises a mixing box, the lower end of the mixing box is fixedly connected with a collecting hopper, the lower end of the collecting hopper is fixedly connected with a separating box, the upper end of the mixing box is provided with a driving motor, the output end of the driving motor is fixedly connected with a rotating rod, and the rotating rod is fixedly connected with a rotating shaft. The precise centrifugal separator comprises a mixing box and a rotating rod, the rotating rod is rotatably connected with the mixing box, the outer side of the rotating rod is fixedly connected with a spiral blade, and the spiral blade is arranged in an inner cavity of the mixing box. According to the levoparoxol separation device, the filter screen is arranged, so that a levoparoxol mixture attached to the upper end of the filter screen can be stirred, the problem that the filter effect is reduced due to the fact that filter holes of the filter screen are blocked by particle impurities can be effectively prevented, and the filtered levoparoxol mixture falls into a separation box through a collection hopper to realize separation of levoparoxol.
Owner:SHOUGUANG HAIMENG CHEMICAL CO LTD